HOME MAJOR NEEDS SCIENCE PRODUCTS PEOPLE PRESS INVESTORS CAREERS REGION PRESS RELEASES PRESS RELEASES EVENTS GELESIS IN THE NEWS Gelesis’ FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer December 01, 2021 Gelesis Receives $30 Million Plenity® Order from Ro November 18, 2021 Nature’s Scientific Reports Features Gelesis’ Novel and Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage November 18, 2021 Two Senior Scientific Leaders at Gelesis Awarded Top Industry Honors November 18, 2021 Gelesis, a Consumer-Focused Biotherapeutics Company and the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp. July 19, 2021 Procter & Gamble Veteran Jane Wildman Joins Gelesis Board of Directors April 26, 2021 New Survey Finds 71 Million Americans Have Gained Weight Throughout the Pandemic December 22, 2020 Gelesis Presents Pre-Clinical Data Suggesting Proprietary Hydrogel (GS300 Prototype) Reverses the Damage to the Intestines Induced by a High Fat Diet November 13, 2020 Gelesis Presents Three Poster Presentations at ObesityWeek® 2020 November 03, 2020 Gelesis to Present New Data at The Obesity Society’s ObesityWeek® and The American Association for the Study of Liver Disease’s The Liver Meeting® November 02, 2020 Plenity® Efficacy and Safety Data to be Presented at the European and International Congress on Obesity 2020 September 04, 2020 Gelesis Announces Partnership for Commercial Launch of Plenity® in China June 18, 2020 Gelesis Receives Approval to Market PLENITY™ in Europe as a Weight Loss Treatment June 02, 2020 Gelesis Named One of the World’s Most Innovative Companies for 2020 by Fast Company March 10, 2020 Gelesis Announces Partnership with Ro on Commercial Launch of Plenity™ December 17, 2019 Gelesis Secures Over $84 Million in New Capital to Support Commercialization of PLENITY™ December 09, 2019 Pivotal Data Presented at ObesityWeek 2019 Highlight the Therapeutic Benefits of Plenity™ in Adults with Obesity and Underscore its Safety and Efficacy in Lower-BMI Overweight Adults November 05, 2019 New Plenity™ Pivotal Safety and Efficacy Data to be Presented at ObesityWeek 2019 October 29, 2019 Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week by Researchers from Massachusetts General Hospital and Brigham and Women’s Hospital May 19, 2019 Gelesis Awarded $10.6 (€9.4) Million Grant to Support Commercial Manufacturing of PLENITY™ April 25, 2019 Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management April 14, 2019 Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Prevents Harmful Effects of a High-Fat Diet April 11, 2019 Gelesis Presents Expanded Data Showing Impact of Gelesis100 Hydrogel on Patients with Prediabetes, Untreated Diabetes, and Elevated Insulin Resistance March 25, 2019 Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Restores Gut Barrier Function March 25, 2019 Gelesis Announces Three Presentations at Annual Endocrine Society Meeting March 21, 2019 Pivotal Weight Loss Data for Gelesis100 Published in Obesity, Including Predictors of Response November 13, 2018 Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018 November 05, 2018 Harry Leider, Former Chief Medical Officer of Walgreens, joins Gelesis as Chief Medical Officer, and Paul Fonteyne, Chairman and Former CEO of Boehringer Ingelheim USA, joins the Gelesis Board of Directors June 06, 2018 Gelesis Raises $30 Million to Prepare for Potential Launch of Lead Product March 01, 2018 Gelesis100 Achieves Significant Weight Loss with Excellent Safety Profile in Pivotal Study September 25, 2017 Gelesis Announces Last Patient Out in the Pivotal Gelesis100 Weight-Loss Study July 12, 2017 Gelesis Announces €2.9 Million Award from Italian Ministry of Economic Development May 03, 2017 Administration of Gelesis200 Increases Fullness and Satiety in People who are Overweight or Have Obesity September 02, 2016 Gelesis Appoints New Chief Operating Officer September 02, 2016 Gelesis Announces Positive Safety Data from First-In-Human Study of Second Product Candidate, Gelesis200 May 03, 2016 Gelesis Announces First U.S. Patient Enrolled in Pivotal Gelesis100 Weight-Loss Study April 26, 2016 Gelesis Closes $31.5 Million Growth Financing December 18, 2015 Gelesis Expands Ongoing Weight Loss Study to Serve as U.S. Pivotal Trial, Significantly Accelerating Development Timeline July 27, 2015 Gelesis Presents Additional Data at European Congress on Obesity May 22, 2015 Gelesis Closes $22M Equity Financing April 01, 2015 Gelesis Announces Initiation of a Six-Month Weight Loss Study with Gelesis100 January 09, 2015 Gelesis Presents Additional Clinical Data at the Obesity Society Annual Meeting November 03, 2014 Gelesis Presents Results of Proof of Concept Weight Loss Study June 23, 2014 Gelesis Expands Team to Advance Further Clinical Development of its Novel Obesity & Diabetes Therapy & Discloses Recent $12M Funding May 16, 2014 Obesity Clinician, Arne Astrup, former President of the International Association for the Study of Obesity, joins Gelesis Advisory Board March 01, 2013 Gelesis Presents New Data at The Obesity Society Annual Meeting October 03, 2011 Gelesis Presents Mechanistic Data Supporting its Novel Clinical Stage Obesity Treatment at Obesity 2010 October 11, 2010 © 2021 Gelesis – All rights reserved Terms and conditions Privacy Policy E.U. GDPR – English | Italian Social Media Community Guidelines Patent Notice Contact